XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.1
SEGMENT INFORMATION
 6 Months Ended
Apr. 30, 2023
Segment Reporting [Abstract]  
SEGMENT INFORMATION

11. SEGMENT INFORMATION

 

We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in four reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics and (iv) Other. The following represents selected financial information for our segments for the three and six months ended April 30, 2023 and 2022 and as of April 30, 2023 and October 31, 2022, in thousands:

  

   2023   2022   2023   2022 
   For the Three Months Ended
April 30,		   For the Six Months Ended
April 30,		 
   2023   2022   2023   2022 
Net income/(loss):                    
CAR-T Therapeutics  $(997)  $(1,399)  $(1,908)  $(3,010)
Cancer Vaccines   (913)   (1,423)   (1,871)   (2,780)
Anti-Viral Therapeutics   (416)   (757)   (898)   (1,661)
Other   19   (9)   16   (16)
Total  $(2,307)  $(3,588)  $(4,661)  $(7,467)
                     
Total operating costs and expenses  $2,770   $3,589   $5,326   $7,469 
Less non-cash stock-based compensation   (1,227)   (1,745)   (2,290)   (4,099)
Operating costs and expenses excluding non-cash stock-based compensation  $1,543   $1,844   $3,036   $3,370 
Operating costs and expenses excluding non-cash stock-based compensation:                    
CAR-T Therapeutics  $620   $733   $1,218   $1,402 
Cancer Vaccines   523    716    1,111    1,196 
Anti-Viral Therapeutics   212    388    517    760 
Other   188    7    190    12 
Total  $1,543   $1,844   $3,036   $3,370 

 

   April 30,
2023		   October 31,
2022		 
Total assets:          
CAR-T Therapeutics  $11,682   $16,921 
Cancer Vaccines   10,638    9,442 
Anti-Viral Therapeutics   

4,953

    3,811 
Other   

326

    238 
Total  $27,599   $30,412 

 

Operating costs and expenses excluding non-cash stock-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.

 

The Company’s consolidated revenue of $210,000 and inventor royalties, contingent legal fees, litigation and licensing expense of $161,000 for the three and six months ended April 30, 2023 were solely related to our encrypted audio/video conference calling technology, which is included in our Other segment. All our revenue is generated domestically (United States) based on the country in which the licensee is located.